In a large study of patients with known or suspected cardiac sarcoidosis, researchers found that FDG-PET could identify those at higher risk of death or life-threatening arrhythmia, according to results published in the February 4 issue of the Journal of the American College of Cardiology. {read more here}

FluoroPharma Medical, based in Montclair, N.J., announced yesterday that new results from an ongoing phase II clinical trial for F-18 FCPHA cardiac PET for the diagnosis of acute coronary artery disease (CAD) were positive and providing validation for further research. {read more here}

In a large study of patients with known or suspected cardiac sarcoidosis, researchers found that FDG-PET could identify those at higher risk of death or life-threatening arrhythmia, according to results published in the February 4 issue of the Journal of the American College of Cardiology. {read more here}

Four up-and-coming radiotracers to target areas of under-oxygenation, which indicates dying tissues and possible tumor proliferation, were compared and found to have similar biodistribution and uptake, according to a study published Feb. 3 in the Journal of Nuclear Medicine. {read more here}